Xiaoyu Zhang1,#, RenFei Zong1,#, Yan Sun1, Nan Chen2, Kunyao Zhu1, Hang Tong1, Tinghao Li1, Junlong Zhu1, Zijia Qin1, Linfeng Wu1, Aimin Wang1, Weiyang He1,*
Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.072084
- 19 January 2026
Abstract Objective: While cisplatin-based chemotherapy is pivotal for advanced bladder cancer, acquired resistance remains a major obstacle. This study investigates key molecular drivers of this resistance and potential reversal strategies. Methods: We established GC (Gemcitabine and Cisplatin)-resistant T24-R and UC3-R cell lines from T24 and UM-UC-3 (UC3) cells. Transcriptomic and proteomic analyses identified differentially expressed molecules. Apoptosis and cell viability were assessed by flow cytometry and CCK-8 (Cell Counting Kit-8) assays, while RT-qPCR (Reverse Transcription Quantitative Polymerase Chain Reaction) and Western blot analyzed gene and protein expression. Immunofluorescence evaluated FAK (Focal Adhesion Kinase) phosphorylation, and a… More >